MigVax is developing an oral COVID-19 sub-unit vaccine. 

The MigVax approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx.


This method, based on the IBV vaccine, generates three kinds of immunological response:

  1. mucosal immunity- IgA

  2. Blood-based immunity-IgG

  3. Cell-mediated immunity.

The MigVax vaccine is based on a vaccine developed for Infectious Bronchitis Virus which is a coronavirus that infects chickens.​

MigVax and OurCrowd raises $12M for its COVID-19 vaccine efforts

Download a Mutual Press Release by MigVax and OurCrowd

MigVax team develop Covid-19 vaccine

Meet the Multidisciplinary MigVax Team


Read about the COVID-19 Pandemic